Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381344 | 1.00 | CRBN (0.73) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL29808178 | 1.00 | CRBN (0.73) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL31563747 | 0.99 | DDB1 (0.75) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL20118479 | 0.93 | DDB1 (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL1424775 | 0.93 | DDB1 (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20118388 | 0.93 | DDB1 (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL3783534 | 0.92 | CRBN (0.72) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL12250832 | 0.91 | CRBN (0.61) | CRBNDDB1BRD4HDAC3HDAC1 | |
| SCHEMBL24938255 | 0.91 | CRBN (0.70) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL2384336 | 0.91 | CRBN (0.70) | CRBNDDB1BRD4IKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | claimed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | claimed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20250381272-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | JUNO THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250242020-A1 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1) | JUNO THERAPEUTICS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | JUNO THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-12268741-B2 | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) | JUNO THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12263190-B2 | Methods and combinations for treatment and T cell modulation | JUNO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240302349-A1 | METHODS OF ASSESSING OR MONITORING A RESPONSE TO A CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4427810-A2 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | Juno Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2005046318-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005044178-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-05-12 | — | — | US | disclosed |
| WO-2004103274-A2 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1320531-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-06-25 | — | — | EP | disclosed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002012242-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CRBN 1511/4885DDB1 3650/4885BRD4 1719/4885 |
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CA13, CA12, CA14 | CRBN 1923/4885DDB1 993/4885BRD4 2872/4885 |
| US-20250242020-A1 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1) | ROR1, RORB, RORC | CRBN 338/4885DDB1 938/4885BRD4 3430/4885 |
| US-12268741-B2 | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) | ROR1, RORB, RORC | CRBN 338/4885DDB1 938/4885BRD4 3430/4885 |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | ICOS, MDM2, XIAP | CRBN 17/4885DDB1 1046/4885BRD4 1201/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CRBN 1511/4885DDB1 3650/4885BRD4 1719/4885 |
| US-20240302349-A1 | METHODS OF ASSESSING OR MONITORING A RESPONSE TO A CELL THERAPY | HAVCR2, ICOS, CD47 | CRBN 754/4885DDB1 1700/4885BRD4 4351/4885 |
| US-20250381272-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | BCL6, BCL3, PBK | CRBN 95/4885DDB1 2802/4885BRD4 787/4885 |
| US-12263190-B2 | Methods and combinations for treatment and T cell modulation | ICOS, MDM2, XIAP | CRBN 17/4885DDB1 1046/4885BRD4 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.